DEWIZ-GOLF
20.10.2021 10:02:08 CEST | Business Wire | Press release
deWiz Golf’s Board, including co-founders Christian Bergh and Markus Westerberg, has announced that Jesper Kärrbrink has been appointed new Chairman of the Board. Kärrbrink brings extensive experience from company leadership roles, currently as chairman of Green Jade Games and previously as CEO of, among others, Svenska Spel, Eniro, Euroflorist, Mr. Green, and Östersunds-Posten.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005415/en/
“On behalf of my co-founder Markus and deWiz's board, it is with great pride that I announce that Jesper has been appointed deWiz's new chairman of the board,” said Christian Bergh, co-founder and COO of deWiz Golf. “After five years of development and research, this has been an exciting year with the launch of deWiz and the future is even more exciting with executives like Jesper helping us guide us towards our strategic vision to revolutionize golf and other sports using our world-class wearable technology. Jesper's global experience will be of great value as deWiz expands across golf-rich markets, including North America, Europe and Asia.”
Launched this summer, deWiz is based on revolutionary wearable technology that combines capturing high-precision data of a golfer's swing in real time and biometric feedback to increase a golfer's pace of learning and consistency.
“deWiz is the perfect example of how technology can help players improve their golf game - at all levels,” said Jesper Kärrbrink, new chairman of deWiz Golf. “Artificial intelligence, data collection and motion sensors have been used for a long time to help elite athletes improve their performance. And what's really fascinating about deWiz is how it delivers this high-tech approach at my level, as a dedicated amateur golfer, through a wearable device that helps me to improve my game anywhere, whether I'm on the course, on the range or practicing on my swing at home.”
Today, golfers in the EU, North America and South Korea can buy deWiz and the company plans to expand with new markets in 2022, including Japan, Australia and South Africa.
DEVELOPED BY EXPERTS, TESTED BY PROS: deWiz has been under development for more than five years and has attracted an impressive list of ambassadors, including Bryson DeChambeau, U.S. Open champion from 2020; Annika Sorenstam, 10-time major-champion; Vijay Singh, 3-time major-champion; Lydia Ko, 2-time major champion; 2016 Open-champion Henrik Stenson; 2019 Houston Open-champion Lanto Griffin; and 2-time world champion in long drive, Tim Burke. deWiz's user-friendly app and wearable technology tracks the exact position of a golfer's hands throughout the swing, providing a 3D analysis and delivers data showing Transition , Backswing Length , Wedge Distance and Tempo . These unique deWiz data points provide measurable values that any avid golfer, professional teacher or world-class player can use to effectively refine their swing. As a Swedish developed and produced product, deWiz is focused on its mission to help golfers around the world increase their enjoyment of the game through innovative technology that increases their pace of learning. At the moment, deWiz sells for $699 and is available in the U.S., Canada, Europe and South Korea (more markets are opening regularly - visit the site for the latest updates). Visit dewizgolf.com for more information on how to improve your swing faster or download the app to demonstrate its features via the Apple App Store or Google Play.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005415/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom